These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9410074)

  • 61. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice.
    de Sarro A; Imperatore C; Mastroeni P; de Sarro G
    J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
    Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
    Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Fundamental and clinical evaluation of imipenem/cilastatin sodium in the field of pediatrics].
    Haruta T; Okura KE; Kuroki S; Yamamoto H; Yamaoka K; Kubo K; Kobayashi Y
    Jpn J Antibiot; 1986 Jul; 39(7):1879-88. PubMed ID: 2945941
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparisons of seizure incidence and adverse experiences between imipenem and meropenem.
    Schranz J
    Crit Care Med; 1998 Aug; 26(8):1464-6. PubMed ID: 9710114
    [No Abstract]   [Full Text] [Related]  

  • 65. [Pharmacokinetic and clinical evaluation of imipenem/cilastatin sodium in neonates and premature infants. A study of imipenem/cilastatin sodium by a perinatal co-research group].
    Fujii R; Sakata H; Inyaku F; Fujita K; Maruyama S; Yoshioka H; Hashira S; Tajima T; Nakazawa S; Sato H
    Jpn J Antibiot; 1989 Apr; 42(4):953-72. PubMed ID: 2671429
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Meropenem: evidence of lack of proconvulsive tendency in mice.
    Patel JB; Giles RE
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():307-9. PubMed ID: 2808213
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A cost comparison of intramuscular versus intravenous imipenem.
    Chin A; Gill MA; Ito MK; Yellin AE; Berne TV; Heseltine PN; Appleman MD
    Hosp Pharm; 1989 Nov; 24(11):905-9. PubMed ID: 10296145
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lucasti et al in the May 2008 issue of Clinical Therapeutics.
    Porath AD
    Clin Ther; 2008 Oct; 30(10):1934; author reply 1934-6. PubMed ID: 19014850
    [No Abstract]   [Full Text] [Related]  

  • 69. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
    Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
    J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system.
    Pestotnik SL; Classen DC; Evans RS; Stevens LE; Burke JP
    Ann Pharmacother; 1993 Apr; 27(4):497-501. PubMed ID: 8477128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM; Drusano GL
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Meropenem. A pharmacoeconomic review of its use in serious infections.
    Holliday SM; Benfield P
    Pharmacoeconomics; 1998 Mar; 13(3):359-77. PubMed ID: 10178661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypotension associated with intravenous haloperidol and imipenem.
    Franco-Bronson K; Gajwani P
    J Clin Psychopharmacol; 1999 Oct; 19(5):480-1. PubMed ID: 10505596
    [No Abstract]   [Full Text] [Related]  

  • 74. Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration.
    Signs SA; Tan JS; Salstrom SJ; File TM
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1400-3. PubMed ID: 1510434
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selecting therapy for serious infections in children: maximizing safety and efficacy.
    Bradley JS
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):405-10. PubMed ID: 9635916
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetics of imipenem in healthy volunteers.
    Norrby SR; Björnegård B; Ferber F; Jones KH
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():109-24. PubMed ID: 6583194
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil].
    Yagi Y; Nawa T; Kurata Y; Shibasaki S; Suzuki H; Kurosawa T
    Jpn J Antibiot; 2009 Jun; 62(3):241-52. PubMed ID: 19882983
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Meropenem in elderly and renally impaired patients.
    Cunha BA
    Int J Antimicrob Agents; 1999 Feb; 11(2):167-77. PubMed ID: 10221422
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Meropenem in elderly and renally impaired patients.
    Cunha BA
    Int J Antimicrob Agents; 1998 May; 10(2):107-17. PubMed ID: 9716287
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prolonged continuous i.v. "desensitization" in Tienam hypersensitivity.
    Confino-Cohen R; Goldberg A; Lang R
    Allergy; 1997 Jun; 52(6):683-4. PubMed ID: 9226072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.